Stock TCRX TSCAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Real-time Estimate Cboe BZX
Other stock markets
 10:26:16 2024-04-29 EDT 		5-day change 1st Jan Change
7.49 USD +2.32% Intraday chart for TScan Therapeutics, Inc. +6.74% +30.36%
04-19 TScan Therapeutics Closes $150.1 Million Securities Offering MT
04-17 TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
TSCAN THERAPEUTICS, INC. Stock TScan Therapeutics, Inc.
+30.36% 369M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.02% 42.75B
B
LONZA GROUP AG Stock Lonza Group AG
+47.87% 41.61B
A
MODERNA, INC. Stock Moderna, Inc.
+12.31% 41.34B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.88% 25.49B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.56% 18.12B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.83% 12.24B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.05% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.89% 11B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TCRX Stock
  4. Ratings TScan Therapeutics, Inc.